Baricitinib treatment for hospitalized patients with severe COVID-19 on invasive mechanical ventilation: a propensity score-matched and retrospective analysis
The present study revealed baricitinib reduced 28-days mortality in severe COVID-19 patients on IMV. The effectiveness of baricitinib in treating patients with severe COVID-19 on IMV needs to be further investigated through future studies.
Authors
- Fugui Yan (ORCID: https://orcid.org/0000-0003-3060-9805)
- Wenqi Diao (ORCID: https://orcid.org/0000-0001-9431-8455)
- Weisong Chen (ORCID: https://orcid.org/0000-0001-6053-0546)
- Yanxiong Mao (ORCID: https://orcid.org/0000-0002-7033-3383)
- Anyi Guo
- Jianxing Lai
- Ying Zhang (ORCID: https://orcid.org/0000-0002-9638-9633)
- Dian Yuan (ORCID: https://orcid.org/0000-0002-0299-2563)
- Hao Zhang
Institutions
- Second Affiliated Hospital of Zhejiang University (CN)
- Jinhua Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-01-22
- DOI
- https://doi.org/10.3389/fmed.2025.1445809
- Citations
- 1
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- Bethune Charitable Foundation
- Zhejiang University